Which has higher valuation and earnings, IBRX or ZLAB?

Zai Lab has higher revenue and earnings than ImmunityBio. Zai Lab is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $113.29M 66.42 -$351.40M -$0.85 N/A Zai Lab $460.16M 4.38 -$175.54M -$1.62 N/A

Is IBRX or ZLAB more profitable?

Zai Lab has a net margin of -39.29% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Zai Lab's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -606.15% N/A -59.53% Zai Lab -39.29% -24.32% -15.52%

Does the media refer more to IBRX or ZLAB?

In the previous week, Zai Lab had 1 more articles in the media than ImmunityBio. MarketBeat recorded 4 mentions for Zai Lab and 3 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 1.24 beat Zai Lab's score of 0.53 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ZLAB or NUVL?

Zai Lab has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zai Lab $460.16M 4.38 -$175.54M -$1.62 N/A Nuvalent N/A N/A -$425.38M -$6.06 N/A

Is ZLAB or NUVL more profitable?

Nuvalent has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -39.29% -24.32% -15.52% Nuvalent N/A -40.11% -35.43%

Does the media favor ZLAB or NUVL?

In the previous week, Nuvalent had 56 more articles in the media than Zai Lab. MarketBeat recorded 60 mentions for Nuvalent and 4 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.53 beat Nuvalent's score of 0.18 indicating that Zai Lab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 19 Very Positive mention(s) 8 Positive mention(s) 18 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media favor ZLAB or PRAX?

In the previous week, Praxis Precision Medicines had 2 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Praxis Precision Medicines and 4 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.53 beat Praxis Precision Medicines' score of 0.37 indicating that Zai Lab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Praxis Precision Medicines 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, PCVX or ZLAB?

Zai Lab has higher revenue and earnings than Vaxcyte. Zai Lab is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$6.88 N/A Zai Lab $460.16M 4.38 -$175.54M -$1.62 N/A

Is PCVX or ZLAB more profitable?

Vaxcyte has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -32.51% -29.51% Zai Lab -39.29% -24.32% -15.52%

Does the media refer more to PCVX or ZLAB?

In the previous week, Vaxcyte had 2 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Vaxcyte and 4 mentions for Zai Lab. Vaxcyte's average media sentiment score of 1.65 beat Zai Lab's score of 0.53 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ZLAB or LNTH?

Lantheus has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zai Lab $460.16M 4.38 -$175.54M -$1.62 N/A Lantheus $1.54B 4.43 $233.56M $4.15 25.27

Is ZLAB or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Zai Lab's net margin of -39.29%. Lantheus' return on equity of 29.32% beat Zai Lab's return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -39.29% -24.32% -15.52% Lantheus 18.05% 29.32% 15.00%

Does the media prefer ZLAB or LNTH?

In the previous week, Zai Lab had 1 more articles in the media than Lantheus. MarketBeat recorded 4 mentions for Zai Lab and 3 mentions for Lantheus. Lantheus' average media sentiment score of 0.63 beat Zai Lab's score of 0.53 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zai Lab (ZLAB) Competitors

$17.76 +0.69 (+4.07%)

As of 12:42 PM Eastern

Compare

ZLAB vs. IBRX, NUVL, PRAX, PCVX, and LNTH

Should you buy Zai Lab stock or one of its competitors? MarketBeat compares Zai Lab with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zai Lab include ImmunityBio (IBRX), Nuvalent (NUVL), Praxis Precision Medicines (PRAX), Vaxcyte (PCVX), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

How does Zai Lab compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Zai Lab (NASDAQ:ZLAB) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

ImmunityBio has a beta of 0.03, meaning that its share price is 97% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 66.1% of ImmunityBio shares are held by company insiders. Comparatively, 4.9% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ImmunityBio currently has a consensus price target of $14.20, suggesting a potential upside of 97.63%. Zai Lab has a consensus price target of $45.83, suggesting a potential upside of 158.01%. Given Zai Lab's higher possible upside, analysts plainly believe Zai Lab is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63

In the previous week, Zai Lab had 1 more articles in the media than ImmunityBio. MarketBeat recorded 4 mentions for Zai Lab and 3 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 1.24 beat Zai Lab's score of 0.53 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Zai Lab has a net margin of -39.29% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Zai Lab	-39.29%	-24.32%	-15.52%

Zai Lab has higher revenue and earnings than ImmunityBio. Zai Lab is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	66.42	-$351.40M	-$0.85	N/A
Zai Lab	$460.16M	4.38	-$175.54M	-$1.62	N/A

Summary

Zai Lab beats ImmunityBio on 9 of the 17 factors compared between the two stocks.

How does Zai Lab compare to Nuvalent?

Zai Lab (NASDAQ:ZLAB) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

In the previous week, Nuvalent had 56 more articles in the media than Zai Lab. MarketBeat recorded 60 mentions for Nuvalent and 4 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.53 beat Nuvalent's score of 0.18 indicating that Zai Lab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	19 Very Positive mention(s)	8 Positive mention(s)	18 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Nuvalent has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-39.29%	-24.32%	-15.52%
Nuvalent	N/A	-40.11%	-35.43%

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 4.9% of Zai Lab shares are held by insiders. Comparatively, 5.0% of Nuvalent shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Zai Lab has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Zai Lab currently has a consensus price target of $45.83, suggesting a potential upside of 158.01%. Nuvalent has a consensus price target of $131.15, suggesting a potential upside of 6.26%. Given Zai Lab's stronger consensus rating and higher probable upside, research analysts plainly believe Zai Lab is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63
Nuvalent	1 Sell rating(s)	14 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

Zai Lab has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	4.38	-$175.54M	-$1.62	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Summary

Zai Lab beats Nuvalent on 10 of the 15 factors compared between the two stocks.

How does Zai Lab compare to Praxis Precision Medicines?

Zai Lab (NASDAQ:ZLAB) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

In the previous week, Praxis Precision Medicines had 2 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Praxis Precision Medicines and 4 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.53 beat Praxis Precision Medicines' score of 0.37 indicating that Zai Lab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Praxis Precision Medicines	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 4.9% of Zai Lab shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Praxis Precision Medicines has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-39.29%	-24.32%	-15.52%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Zai Lab has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market.

Zai Lab has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	4.38	-$175.54M	-$1.62	N/A
Praxis Precision Medicines	$8.55M	868.94	-$303.27M	-$13.37	N/A

Zai Lab presently has a consensus target price of $45.83, suggesting a potential upside of 158.01%. Praxis Precision Medicines has a consensus target price of $572.72, suggesting a potential upside of 114.92%. Given Zai Lab's higher possible upside, analysts clearly believe Zai Lab is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95

Summary

Zai Lab beats Praxis Precision Medicines on 9 of the 17 factors compared between the two stocks.

How does Zai Lab compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Zai Lab (NASDAQ:ZLAB) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Vaxcyte has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

Vaxcyte currently has a consensus target price of $86.00, indicating a potential upside of 75.03%. Zai Lab has a consensus target price of $45.83, indicating a potential upside of 158.01%. Given Zai Lab's higher possible upside, analysts plainly believe Zai Lab is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by insiders. Comparatively, 4.9% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Vaxcyte had 2 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Vaxcyte and 4 mentions for Zai Lab. Vaxcyte's average media sentiment score of 1.65 beat Zai Lab's score of 0.53 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Zai Lab has higher revenue and earnings than Vaxcyte. Zai Lab is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Zai Lab	$460.16M	4.38	-$175.54M	-$1.62	N/A

Vaxcyte has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Zai Lab	-39.29%	-24.32%	-15.52%

Summary

Zai Lab beats Vaxcyte on 8 of the 15 factors compared between the two stocks.

How does Zai Lab compare to Lantheus?

Zai Lab (NASDAQ:ZLAB) and Lantheus (NASDAQ:LNTH) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Zai Lab had 1 more articles in the media than Lantheus. MarketBeat recorded 4 mentions for Zai Lab and 3 mentions for Lantheus. Lantheus' average media sentiment score of 0.63 beat Zai Lab's score of 0.53 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 18.05% compared to Zai Lab's net margin of -39.29%. Lantheus' return on equity of 29.32% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-39.29%	-24.32%	-15.52%
Lantheus	18.05%	29.32%	15.00%

Zai Lab presently has a consensus price target of $45.83, suggesting a potential upside of 158.01%. Lantheus has a consensus price target of $101.86, suggesting a potential downside of 2.88%. Given Zai Lab's higher possible upside, equities research analysts clearly believe Zai Lab is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 4.9% of Zai Lab shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lantheus has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	4.38	-$175.54M	-$1.62	N/A
Lantheus	$1.54B	4.43	$233.56M	$4.15	25.27

Zai Lab has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market.

Summary

Lantheus beats Zai Lab on 12 of the 17 factors compared between the two stocks.

Get Zai Lab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZLAB vs. The Competition

Export

Metric	Zai Lab	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.01B	$3.40B	$6.50B	$12.37B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-10.96	20.08	24.01	24.71
Price / Sales	4.38	326.19	540.55	165.59
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	2.78	8.11	10.55	6.85
Net Income	-$175.54M	$23.89M	$3.56B	$337.45M
7 Day Performance	7.79%	3.36%	1.54%	2.70%
1 Month Performance	-13.73%	1.34%	2.48%	4.60%
1 Year Performance	-56.67%	46.46%	26.49%	32.81%

Zai Lab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZLAB Zai Lab	2.7464 of 5 stars	$17.76 +4.1%	$45.83 +158.0%	-58.4%	$2.01B	$460.16M	N/A	1,784	Gap Up
IBRX ImmunityBio	3.483 of 5 stars	$7.17 +3.6%	$14.20 +98.0%	+131.3%	$7.25B	$113.29M	N/A	590	Positive News Gap Up
NUVL Nuvalent	1.8151 of 5 stars	$88.49 -2.7%	$141.24 +59.6%	+57.5%	$7.18B	N/A	N/A	40
PRAX Praxis Precision Medicines	2.6591 of 5 stars	$253.25 -0.3%	$572.72 +126.1%	+501.8%	$7.08B	$8.55M	N/A	110
PCVX Vaxcyte	2.8182 of 5 stars	$46.33 -2.2%	$86.00 +85.6%	+37.3%	$6.84B	N/A	N/A	160	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZLAB) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zai Lab (ZLAB) Competitors